caa a22 4500 475806174 CHVBK 20180406123747.0 cr unu---uuuuu 170329e20000601xx s 000 0 eng 10.1023/A:1026500431505 doi (NATIONALLICENCE)springer-10.1023/A:1026500431505 Schirner Michael Research Laboratories of Schering AG, Berlin, Germany aut Antiangiogenic Chemotherapeutic Agents [Elektronische Daten] [Michael Schirner] The mechanism of action of anticancer chemotherapeutic agents is mainly thought to be due to a direct inhibition of tumor cell proliferation. The enhanced endothelial cell proliferation rate in tumor specimens raised the question whether therapeutic effects of chemotherapeutic agents might be at least partially attributed to an inhibition of tumor angiogenesis. Meanwhile, numerous anticancer chemotherapeutic agents were tested for their antiangiogenic potential. A few agents seem to exert consistent inhibition of tumor angiogenesis even in drug-resistant tumors. Most recent investigations on the antiangiogenic efficacy of different application schedules suggested the use of a tightly spaced, continuous application of appropriate anticancer chemotherapeutic agents. These application schedules are able to exert a strong antiangiogenic effect as indicated by an increase of apoptosis of tumor endothelial cells. Future clinical trials have to determine the therapeutic benefit of novel combination chemotherapy and alternative application schedules. Kluwer Academic Publishers, 2000 chemotherapy nationallicence angiogenesis nationallicence durg treatment nationallicence dose scheduling nationallicence Cancer and Metastasis Reviews Kluwer Academic Publishers 19/1-2(2000-06-01), 67-73 0167-7659 19:1-2<67 2000 19 10555 https://doi.org/10.1023/A:1026500431505 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1023/A:1026500431505 text/html Onlinezugriff via DOI NATIONALLICENCE 100 1- Schirner Michael Research Laboratories of Schering AG, Berlin, Germany aut NATIONALLICENCE 773 0- Cancer and Metastasis Reviews Kluwer Academic Publishers 19/1-2(2000-06-01), 67-73 0167-7659 19:1-2<67 2000 19 10555 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer